COMMUNIQUÉS West-GlobeNewswire

Kexing Biopharm’s Biologics License Application for Long-Acting G-CSF Candidate GB-K02 Accepted for Review
16/10/2026
SAN DIEGO, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Kexing Biopharm (688136.SH) recently announced that it has received a Notice of Acceptance from China’s National Medical Products Administration (NMPA) for the biologics [...]
CHMP recommends approval of Johnson & Johnson’s TALVEY®▼ (talquetamab) plus daratumumab in earlier line treatment of relapsed/refractory multiple myeloma
16/10/2026
If approved, TALVEY ® plus daratumumab will be the only GPRC5D-targeting bispecific antibody combination therapy for relapsed or refractory multiple myeloma as early as second line CHMP recommendation based on Phase 3 [...]
Semax Peptide Introduced by Kylo Peptides for Laboratory Use
16/10/2026
Sheridan, Wyoming, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Kylo Peptides has added Semax [ https://kylopeptides.com/product/semax/ ] to its research catalog this week. The compound is a synthetic peptide supplied only for [...]
OXB Appoints Joachim Kreuzburg as Independent Non-Executive Director
16/10/2026
OXB Appoints Joachim Kreuzburg as Independent Non-Executive Director Oxford, UK – 16 October 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces the appointment of Dr [...]
FDA approves Roche’s Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)
16/10/2026
FDA approval based on Phase III SatraGO-1 and -2 studies, with SatraGO-2 demonstrating a significant reduction in eye bulging (proptosis) and improvement in diplopia (double vision), with a favourable safety profile, [...]
IBA et Framatome s’associent pour industrialiser la production d’Astate-211 au service des thérapies contre le cancer
16/10/2026
Louvain-la-Neuve, Belgique, et Paris, France, le 16 octobre 2026, 8h00 – IBA (Ion Beam Applications, EURONEXT), leader mondial des technologies d'accélérateurs de particules et des solutions de production en médecine [...]
IBA and Framatome join forces to industrialize Astatine-211 production for cancer therapies
16/10/2026
Louvain-la-Neuve, Belgium, and Paris, France, 16 October 2026, 8:00 a.m. – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and radiopharmaceutical production solutions, [...]
Three Orelabrutinib Studies Presented in Oral Sessions at the 88th Annual Meeting of the Japanese Society of Hematology
16/10/2026
BEIJING, Oct. 16, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that three studies [...]
Senturi Pharma announces exclusive European distribution agreement for PERTZYE®
16/10/2026
STOCKHOLM, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Senturi Pharma AB and Digestive Care, Inc. today announced the signing of an exclusive distribution agreement concerning PERTZYE ® (pancrelipase) in Europe. Under the [...]
City Therapeutics Announces Pricing of Upsized Initial Public Offering
16/10/2026
CAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) -- City Therapeutics, Inc. (Nasdaq: CTY) (“City” or “City Therapeutics”), a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi [...]
Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Enrolls First Patient in Phase Ib/II Combination Trial in Metastatic Colorectal Cancer
16/10/2026
Extending the Company's Immunologically Cold Tumor Strategy into Colorectal Cancer NANJING, China , Oct. 16, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887. [...]
Anavex Receives FDA Clearance of its IND Application for Blarcamesine in Fragile X Syndrome
15/10/2026
Anavex now has open INDs in all three core indications: Alzheimer's disease, Rett syndrome, and Fragile X syndrome Phase 2a study will evaluate the safety, tolerability and pharmacokinetics of blarcamesine oral solution [...]
MDxHealth Announces Preliminary Third Quarter 2026 Revenue and Suspends Full-Year 2026 Revenue Guidance
15/10/2026
IRVINE, CA – October 15, 2026 ( GlobeNewswire ) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced preliminary unaudited revenue from [...]
Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026
15/10/2026
OPGx-BEST1 showed improved retinal sensitivity in 75% of evaluable participants in the initial low-dose Cohort 1 of the Company’s Phase 1/2 clinical trial, supporting further clinical development New BEST1 data analyses [...]
Syndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 List
15/10/2026
NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj ® (revumenib), the [...]
Données Complètes à 12 Mois de l’Étude Pivot Américaine ACCCESS chez les Patients Atteints de Collapsus Concentrique Complet Présentées à l’ISSS 2026
15/10/2026
Données Complètes à 12 Mois de l’Étude Pivot Américaine ACCCESS chez les Patients Atteints de Collapsus Concentrique Complet Présentées à l’ISSS 2026 La stimulation bilatérale Genio® a permis une réduction médiane de 74 [...]
Full 12-Month Data from the ACCCESS U.S. Pivotal Study in Complete Concentric Collapse Patients Presented at ISSS 2026
15/10/2026
Full 12-Month Data from the ACCCESS U.S. Pivotal Study in Complete Concentric Collapse Patients Presented at ISSS 2026 Genio® bilateral stimulation delivered a 74.3% median reduction in AHI at 12 months, with no device [...]
MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid Tumors
15/10/2026
ROCKVILLE, MD, Oct. 15, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, [...]
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
15/10/2026
CONSHOHOCKEN, Pa., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated [...]

Pages